Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
PMV Pharmaceuticals Stock
PMV Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David H. Mack
- Employees
- 54
- Market cap
- $72 M
- IPO
- 25/09/2020
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it…
PMV Pharmaceuticals stock: price history
1D
-4.3%
1W
-16.1%
1M
-3.6%
6M
-8.2%
YTD
+8.0%
1Y
+2.3%
2Y
-9.4%
5Y
-94.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about PMV Pharmaceuticals
Analyst assessment of PMV Pharmaceuticals
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 04/09/2026
PMV Pharmaceuticals stock metrics
P/E
-0.95
P/B
1.01
EV/EBITDA
-0.79
RETURN ON EQUITY
-25.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.7%
FLOAT SHARES
48,896,034
AVG. DAILY VOLUME (30D)
1,065,593
Institutional holders
Comparable stocks
Frequently asked questions about PMV Pharmaceuticals stock
What does PMV Pharmaceuticals do?
PMV Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David H. Mack, the company employs around 54 people.
The IPO was on 25/09/2020; the stock trades on NASDAQ under the ticker PMVP.
What do analysts say about PMV Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Buy (as of 04/09/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does PMV Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does PMV Pharmaceuticals pay a dividend?
No, PMV Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to PMV Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get PMV Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess PMV Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.